EIF4A1 and diffuse large B-cell lymphoma: 3) The most recent publication using HINT in this way (Kayastha et al., 2022) details the discovery of three new potent eIF4A inhibitors that diminished the viability of diffuse large B-cell lymphoma (DLBCL) cells.